Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma

Cancer Biology and Therapy

Volumn 3, Issue 9, 2004, Pages 891-898

  Dong, Hai Long ^a   Li, Zeng Shan ^a   Ye, Jing ^a   Qu, Ping ^a   Huang, Ya Yu ^a   Wu, Wen ^a   Lu, Shao Ying ^a   Chen, Guang Sheng ^a   Sui, Yan Fang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CTL epitope; HCC; MAGE n; Tumor antigen; Tumor vaccine

Indexed keywords

AMINO ACID DERIVATIVE; EPITOPE; GLUTAMINYLLEUCYLVALYLPHENYLALANYLGLYCYLISOLEUCYLGLUTAMYLVALYLVALINE; HLA A2 ANTIGEN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALINE; CANCER VACCINE; MAGEA6 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ACCURACY; ARTICLE; CELL STIMULATION; CHINA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; LIVER CELL CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; AMINO ACID SEQUENCE; FORECASTING; GENETICS; IMMUNOLOGY; LIVER TUMOR; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; EPITOPES; FORECASTING; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 18744395235     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.9.1081     Document Type: Article

References (34)

1. Boel P, Wildmann C, Sensi ML, Renauld JC, Coulie P, Boon T, et al. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2:167-75.
2. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-47.
3. Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol 2000; 30:117-21.
4. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:3-15.
5. Li J, Yang Y, Fujie T, Baba K, Ueo H, Mori M, et al. Expression of BAGE, GAGE, and MAGE genes inhuman gastric carcinoma. Clin Cancer Res 1996; 2:1619-25.
6. Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang XW, et al. The cloning of tumor-associated gene MAGE in human heptatocellular carcinoma cell line. Chin J Cell Mol Immunol 2002; 18:270-4.
7. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35:S86-91.
8. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther 2002; 2:123-33.
9. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, et al. Treatment of nonresectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17:889-96.
10. Li Z, Sui Y, Jiang Y, Lei Z, Shang J, Zheng Y. Reconstruction of SEA-B7.1 double signals on human hepatocellular carcinoma cells and analysis of its immunological effect. Biochem Biophys Res Commun 2001; 288:454-61.
11. Li ZS, Yang XW, Chen Z, Dong HL, Ye J, Qu P, et al. In Vivo tumor Cotransfection with superantigen and CD80 induces systemic immunity without tolerance and prolongs survival in mice with hepatocellular carcinoma. NA: Cancer Biol Ther 2004; In press.
12. Lu SY, Sui YF, Li ZS, Ye J, Dong HL, Qu P, et al. Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study. World J Gastroenterol 2004; 10:53-7.
13. Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY, Sun ZT. Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin J Immunol 1999; 15:305-10.
14. + T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol 2001; 1:1235-47.
15. + T lymphocytes from patients with bladder cancer. Hum Immunol 2001; 62:791-8.
16. + cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res 2003; 112:189-97.
17. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: Toward second-gene ration tumor antigens. Trends Immunol 2001; 22:516-23.
18. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, et al. Efficient identification of novel HLA-A*0201- presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193:73-88.
19. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxicT lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59:2675-81.
20. Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002; 8:3885-92.
21. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7:452-8.
22. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-plused mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage melanoma. J Exp Med 1999; 190:1669-78.
23. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Med Pediatr Oncol 2002; 38:158-64.
24. Rammensee HG, Bachmann J, Emmerich NPN, Bachor OA, Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-19.
25. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929-37.
26. Marshall KW, Wilson KJ, Liang J, Woods A, Zaller D, Rothbard JB. Prediction of peptide affinity to HLA DRB1-0401. J Immunol 1995; 154:5927-33.
27. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains. J Immunol 1994; 152:163-75.
28. Hammer JE, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility comlex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994; 180:2353-8.
29. Hammer J. New methods to predict MHC-binding sequences within protein antigens. Curr Opin Immunol 1995; 7:263-9.
30. Andersen MH, Keikavoussi P, Brocker EB, Schuler TB, Jonassen M, Sondergaard I, et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancer 2001; 94:820-4.
31. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96:3102-8.
32. Eifuku R, Takenoyama M, Yoshino I, Imahayashi S, So T, Yasuda M, et al. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int J Clin Oncol 2001; 6:34-9.
33. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: Implication in a broad-spectrum tumor immunotherapy. J Immunol 2002; 169:575-80.
34. Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, et al. Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: Intracellular loading and kinetics of presentation. J Immunol 2001; 167:2529-37.